Pykus Therapeutics to Present Initial Clinical Data on Novel Retinal Sealant

Pykus Therapeutics announced that it will present initial clinical data on its investigational retinal sealant, PYK-2101, to replace gas and oil during retinal detachment repair.

The data will be presented at the Vail Vitrectomy 2025 Meeting on February 10, 2025. The presentation will provide new insights into the development and clinical progress of PYK-2101, Pykus' lead investigational device designed to improve surgical outcomes and patients' postoperative experience compared to the current standard of care.

Presentation Details:

• Title: Use of Focal Retinal Sealants in Retinal Detachment Repair: Pilot Clinical Study Results
• Presenter: James A. Stefater, MD, PhD, President and Cofounder, Pykus Therapeutics
• Time: February 10, 2025, 6:30 am MST

"More than 125,000 people undergo retinal reattachment procedures on a yearly basis in the US. Although our success rate is high, the current recovery process is uncomfortable and inconvenient for patients. In particular, the postoperative positioning requirements and limited vision associated with intraocular gas bubbles are significant limitations to a return to normal life. The Pykus solution would be a transformative advance," Carl Awh, MD, a retina specialist with Tennessee Retina, said in a company news release.

According to Pykus, PYK-2101 is a novel, patented biodegradable hydrogel developed to improve the surgical recovery experience by directly sealing retinal breaks without obscuring vision, and eliminates the need to position face-down. The sealant is intended to be safer and more effective during retina surgery compared to silicone oil or medical gases. This new approach aims to improve patient outcomes and patient experience after surgery.